Lead Product(s) : Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Camizestrant (AZD9833) is a potent, next-generation oral SERD and pure ERα antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations.
Product Name : AZD9833
Product Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2022
Lead Product(s) : Camizestrant,Palbociclib,Luteinizing Hormone
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
